Earnings
Firm’s future, as a separate business nearly 90% owned by Bausch Health, or as a standalone with different ownership or one not controlled by a majority owner, claims high profile in analysts’ comments and predictions. B+L is in the driver’s seat, they say.
Haleon highlighted consistent market share gains in China as it reported third-quarter results.
French public sector investment bank Bpifrance's influence over the future strategy of Opella extends to its one seat on the company's board, but not past that, Sanofi confirms as it reports Q3 results.
A better than expected showing from its Health business in its latest quarter has teed up Reckitt for a big finish to the year.
Kenvue may have to start sharing time with Bausch + Lomb in investors’ discussions about the outlook for success at US consumer health firms separated from former parent firms as they and their competitors begin reporting the results for their latest quarters.
Major Europe-based consumer health players Sanofi, Haleon, Reckitt and Bayer feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q3 2024 results over the coming weeks.
An end to litigation filed by institutional investors, insurance companies and pension funds comes four CEOs after Perrigo's chief exec during Mylan's tender in 2015, Joseph Papa, resigned to lead another firm in 2016. Plaintiff attorneys are asking for up to 20% of settlement in fees.
Intensified competition in the dietary supplements market and consumers squeezed by cost-of-living pressures held back sales at Dermapharm's Arkopharma subsidiary in the first half. A leadership change, along with a renewed focus on commercial excellence, is hoped by Dermapharm to turn the business around.
Germany's Stada Arzneimittel has secured the rights to market the FITO self-care medical device in the Gulf Cooperation Council region, North Africa, the Middle East and selected Asian Countries, and the Nizoral antifungal cream in Vietnam, the Philippines and Thailand. Stada’s half-year results show that the company’s emerging markets strategy is delivering results, with MENA and APAC contributing to the growth recorded by the Consumer Healthcare division.
Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.
OTC erectile dysfunction treatment Eroxon has made it to the Nordics through local distributor Navamedic, which has reported strong consumer uptake.
OTC sales edged up at Italy's Recordati in the first half of 2024 as higher demand for GI products and supplements offset a weaker cold & flu season.
Herbalife adds distributors and training as sales slow; Amphastar bullish on Primatene Mist $100M full-year target; and ChromaDex net sales up 12%.
“We continue to believe that taking care of your health or someone in your family is the last place to look to make a change or save a few pennies,” says CEO Ron Lombardi. Firm more frequently using air freight services so Clear Eyes products are on store shelves when consumers expect.
Plant-based digestive health remedy Iberogast, alongside Bepanthen Derma and Supradyn dietary supplements, are the brands currently driving sales growth at Bayer Consumer Health, according to the firm's Q2 financial report.
Kenvue maintains full-year guidance after 0.3% Q2 net sales dip beat market expectations. Essential health segment alone drove sales; self-care and skin health/beauty faltered. US sales of Neutrogena Collagen Bank pre-aging platform launched on TikTok shop, a first for the brand.
Church & Dwight’s slower sales at retail in June-July than in January-May point to still slower results for rest of year. It doesn’t expect second-half help from gummy vitamin lines or give them a full vote of confidence for remaining in portfolio.
OTC private label/store brand product giant’s Q2 net sales down 10.7% to $1.1bn, but women’s health product sales jump 31.4% largely on Opill launched late in Q1. Biggest hit to results from infant formula business, down a reported 82% due to ongoing manufacturing quality-control remediation.
Haleon has begun reformulating phenylephrine-containing oral decongestants marketed in the US as the company looks to get ahead of an anticipated FDA decision on the ingredient's use in OTC cough and cold products. The UK-based consumer health manufacturer revealed its plan as it reported organic sales up 3.5% in the first half of 2024.
Brimonidine tartrate eye drops remain key sales driver among Canadian firm’s consumer health lines with 12% growth in the latest quarter. B+L expects pending launch of preservative-free line extension to sustain Lumify as a driver as generics of original formulation are approved.